Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
boston top stories
clinical trials
drugs
inotersen
life sciences
national blog main
2
×
national top stories
new york blog main
new york top stories
patisiran
san diego blog main
2
×
san diego top stories
tafamidis
alnylam pharmaceuticals
anylam pharmaceuticals
barry greene
biotech
boston
boston university
cardiomyopathy
dan ollendorf
fda
hereditary transthyretin amyloidosis
john berk
mary o'donnell
neuropathy
new york
onpattro
pfizer
regeneron pharmaceuticals
rna interference
san francisco blog main
san francisco top stories
tegsedi
the amyloidosis foundation
the institute for clinical and economic review
transthyretin amyloidosis
vyndaqel
What
ago
2
×
alnylam
2
×
fda
patients
akcea
amyloidosis
approve
approved
attr
available
awaits
battle
biological
crossed
debilitating
decades
decision
discovered
disease
drug
fingers
friday
genetic
historic
medicine
medicines
oks
pfizer
rare
rna
sets
time
transthyretin
trick
uses
year
Language
Current search:
ago
×
" national blog main "
×
alnylam
×
" san diego blog main "
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
6 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision